ORCA BIO
Orca Bio is a clinical-stage cell therapy company dedicated to delivering curative medicine to patients. Orca Bio has developed a pipeline of proprietary technologies that have the potential to impact over 100 malignant and auto-immune diseases. Orca has assembled a team of world-leading experts and technologists to execute this vision.
ORCA BIO
Industry:
Health Care Medical Pharmaceutical
Founded:
2016-01-01
Address:
Menlo Park, California, United States
Country:
United States
Website Url:
http://www.orcabio.com
Total Employee:
101+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
192 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Google Universal Analytics Global Site Tag
Similar Organizations
Arcellx
Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.
Osteal Therapeutics
Osteal Therapeutics is a clinical stage specialty pharmaceutical company developing novel treatments for orthopedic infections.
Portal Instruments
Portal Instruments is an early stage company that offers medical device.
Scilex Pharmaceuticals
Scilex Pharmaceuticals is an emerging pharmaceutical company focused on acquiring and commercializing late-stage prescription products.
TOT BIOPHARM
TOT BIOPHARM is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative oncology drugs.
Truepill
Truepill provides an API-connected healthcare infrastructure designed to revolutionize the patient experience.
Current Advisors List
Current Employees Featured
Founder
Investors List
Lightspeed Venture Partners
Lightspeed Venture Partners investment in Series D - Orca Bio
Dream Variation Ventures
Dream Variation Ventures investment in Series D - Orca Bio
Blue Chip Venture Company
Blue Chip Venture Company investment in Series D - Orca Bio
IMRF
IMRF investment in Series D - Orca Bio
DCVC Bio
DCVC Bio investment in Series D - Orca Bio
Kaiser Family Foundation
Kaiser Family Foundation investment in Series D - Orca Bio
Mubadala
Mubadala investment in Series D - Orca Bio
8VC
8VC investment in Series D - Orca Bio
Kaiser Permanente
Kaiser Permanente investment in Series D - Orca Bio
+ND Capital
+ND Capital investment in Series D - Orca Bio
Official Site Inspections
http://www.orcabio.com Semrush global rank: 5.1 M Semrush visits lastest month: 1.6 K
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Orca Bio"
Orca Bio | Who We Are
Orca Bio’s lead investigational allogeneic T-cell immunotherapy, Orca-T, is being evaluated in a pivotal Phase 3 trial called Precision-T for the treatment of acute myeloid leukemia (AML), …See details»
Join Our Team - Orca Bio
Our team of leading scientists, engineers, clinicians and industry professionals are united in our mission to transform the lives of patients, their families and providers through our high-precision approach.See details»
Orca Bio - Crunchbase Company Profile & Funding
Contact Email [email protected] Orca Bio is a clinical-stage cell therapy company dedicated to delivering curative medicine to patients. Orca Bio has …See details»
Orca Bio - LinkedIn
Orca Bio is a late-stage biotechnology company developing high-precision cell therapies for the treatment of cancer and autoimmune diseases. Our investigational products are designed to safely ...See details»
Orca Bio 2025 Company Profile: Valuation, Funding
Orca Bio General Information Description. Developer of cell therapy products designed to replace patients' diseased blood and immune systems with healthy ones. The company specializes in the research and development of novel cell …See details»
Orca Bio: Contact Details, Revenue, Funding, Employees and …
Orca Bio is a late-stage biotechnology company developing high-precision cell therapies for cancer and autoimmune diseases. Using single-cell precision, Orca Bio’s innovative products …See details»
Orca Bio | The Healthcare Technology Report.
Key Executives. Ivan Dimov, PhD, CEO and Co-Founder. Ivan launched Orca Bio in 2016 and is Chief Executive Officer of Orca Bio. He is also co-founder and former Chief Technology Officer …See details»
Working At Orca Bio: Company Overview and Culture - Zippia
Mar 14, 2024 orcabio.com. Organization Type. Private. Social Media. Orca Bio is helping to deliver the promise of cell therapy to patients without compromise. Based in Menlo Park, CA, …See details»
Orca Bio Expands in Greater Sacramento Building New
Sep 8, 2022 For more information, visit www.orcabio.com and follow Orca Bio on Twitter: @orcabio. ... The organization spearheads community-led direction to retain, attract, grow and …See details»
Our Pipeline - Orca Bio
Precision-T (NCT05316701) is a randomized, multicenter Phase 1b/3 study evaluating the safety, tolerability and efficacy of Orca-T, an allogeneic T-cell immunotherapy, in adult patients with …See details»
Orca Bio - Craft
Orca Bio is a company that provides a medical therapy platform intended to develop cell therapies to increase the immunity of the human body. The company specializes in the research and …See details»
Orca Bio breaches the surface with $192M for 'high precision' cell ...
Jun 17, 2020 The series D, drawn from Lightspeed Ventures, 8VC, DCVC Bio, ND Capital, Mubadala investment Company, Kaiser Foundation Hospitals, Kaiser Permanente Group Trust …See details»
Orca Bio Emerges With Nearly $300 Million to Transform
Jun 17, 2020 Media Contact: [email protected]. Twitter; LinkedIn; Facebook; Email Print IPO. LATEST. Business. Elevation Mulls Strategic Alternatives, Including Closure, Amid Activist …See details»
Orca Bio Expands in Greater Sacramento Building New State-of …
Sep 8, 2022 For more information, visit www.orcabio.com and follow Orca Bio on Twitter: @orcabio. About the Greater Sacramento Economic Council The Greater Sacramento …See details»
Orca Bio Emerges With Nearly $300 Million to Transform
Jun 17, 2020 Company aims to safely and effectively regenerate a healthy blood and immune system for patients with hematological malignancies, genetic diseases and...See details»
Orca Bio Emerges With Nearly $300 Million to Transform …
Jun 17, 2020 Company aims to safely and effectively regenerate a healthy blood and immune system for patients with hematological malignancies, genetic diseases and autoimmune …See details»
Achieve Life Sciences Announces Cytisinicline Phase 3
3 days ago Geneva: World Health Organization, 2017. 3 U.S. Department of Health and Human Services. The Health Consequences of Smoking – 50 Years of Progress. A Report of the …See details»
Orca Bio Announces Positive Results from the Pivotal Phase 3 …
MENLO PARK, CA, March 17, 2025 – Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today announced …See details»
Orca Bio | What We Do
Orca Bio has built its own centralized 100,000 square foot manufacturing facility to ensure consistent and reliable delivery of our high-precision cell therapies at scale, with donor to …See details»
Newsroom - Orca Bio
Dec 7, 2024 Orca Bio Presents Positive Phase 1 and 1b Data on Orca-T and Orca-Q at the 2025 Tandem Meetings of ASTCT® and CIBMTR® ViewSee details»